EANM甲状腺髓样癌PET/CT成像实践指南
本实践指南由欧洲核医学协会(EANM)甲状腺委员会联合外部专家制定,基于更新文献证据,针对甲状腺髓样癌患者,规范氟-18氟代脱氧葡萄糖(18F-FDG)、氟-18二羟基苯丙氨酸(18F-FDOPA)及镓-68标记生长抑素类似物(68Ga-SSA)等放射性药物PET/CT的推荐、操作与结果解读。
要点
- 甲状腺髓样癌源于滤泡旁C细胞,可散发或遗传,手术是主要治愈手段。
- 18F-FDG、18F-FDOPA和68Ga-SSA PET/CT可追踪不同代谢通路或受体表达,有助于探测复发/转移。
- 指南旨在帮助影像专家和临床医生在甲状腺髓样癌患者中推荐、执行和解读多种放射性药物PET/CT。
核心结论
- 该EANM甲状腺委员会实践指南基于更新文献证据,为甲状腺髓样癌患者多种放射性药物PET/CT的推荐、操作和结果解读提供建议。
研究设计与样本
- 欧洲核医学协会(EANM)甲状腺委员会联合外部专家制定的实践指南,基于更新文献证据。
诊断标准与关键数值
- 术前分期采用超声检查,选定病例采用横断面解剖成像;探测持续/复发疾病可采用不同的解剖/形态学和功能/分子成像。
- 18F-FDG、18F-FDOPA和68Ga-SSA PET/CT追踪不同代谢通路或受体表达/功能,已证明有助于探测甲状腺髓样癌复发/转移。
临床应用与阅片要点
- 指南旨在协助影像专家和临床医生在甲状腺髓样癌患者中推荐、执行和解读多种放射性药物PET/CT结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure.
METHODS: Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (18F-FDG), fluorine-18 dihydroxyphenylalanine (18F-FDOPA) and somatostatin analogues labelled with gallium-68 (68Ga-SSA) tracks different metabolic pathways or receptor expression/functioning, and proved to be useful in detecting MTC recurrences/metastasis.
CONCLUSIONS: This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature's evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
引用
- Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31482429. doi:10.1007/s00259-019-04458-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。